

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/076350 A1

(51) International Patent Classification:

A61K 31/517 (2006.01) *A61K 31/505* (2006.01)
A61K 31/366 (2006.01) *A61K 45/06* (2006.01)
A61K 31/40 (2006.01) *A61P 37/06* (2006.01)
A61K 31/4439 (2006.01) *A61P 43/00* (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2024/049962

(22) International Filing Date:

04 October 2024 (04.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/588,359 06 October 2023 (06.10.2023) US

(71) Applicant: **KADMON CORPORATION, LLC** [US/US];

55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventor: **SAHI, Jasminder**; c/o Sanofi, Patent Depart-

ment, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **HERZFELD, Deborah M.** et al.; McNeill PLLC,

245 First Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF ADMINISTERING BELUMOSUDIL IN COMBINATION WITH TRANSPORT PROTEIN SUBSTRATES

(57) Abstract: The present disclosure relates to the co-administration of belumosudil and transport protein substrates, such as substrates of organic anion transporting polypeptide 1B1 (OATP1B1), breast cancer resistance protein (BCRP), and P-glycoprotein (P-gp), for use in the treatment of subjects with chronic graft-versus-host disease (cGVHD).

WO 2025/076350 A1